Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19960851 | 0.95 | HRH3 (0.33) | CCR2KCNH2HRH3DRD2DRD3 | |
| SCHEMBL18595816 | 0.91 | KCNH2 (0.34) | CCR2KCNH2CYP2D6GHSRDRD2 | |
| SCHEMBL18633843 | 0.90 | HRH3 (0.33) | HRH3 | |
| SCHEMBL24951509 | 0.90 | MEN1 (0.33) | CCR2KCNH2HRH3 | |
| SCHEMBL19102078 | 0.90 | SIGMAR1 (0.36) | CCR2KCNH2HRH3DRD2DRD3 | |
| SCHEMBL19570341 | 0.89 | SIGMAR1 (0.36) | CCR2KCNH2CYP2D6HRH3GHSR | |
| SCHEMBL22333287 | 0.88 | CCR2 (0.31) | CCR2KCNH2 | |
| SCHEMBL19380559 | 0.87 | HRH3 (0.31) | HRH3 | |
| SCHEMBL21449154 | 0.86 | CHRM5 (0.35) | CCR2KCNH2CYP2D6HRH3GHSR | |
| SCHEMBL23867553 | 0.85 | KDM4E (0.33) | CCR2KCNH2CYP2D6HRH3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379084-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662193-B2 | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins | APP, BACE1, PSEN1 | CCR2 1686/4885KCNH2 4177/4885CYP2D6 3595/4885 |
| US-20210379084-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | CCR2 1372/4885KCNH2 4479/4885CYP2D6 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.